|
Patent landscape, scope, and claims: |
United States Patent 8,043,628: Scope, Claim-by-Claim Read-Through, and U.S. Landscape
What does US 8,043,628 claim, at a technical level?
US 8,043,628 claims a method-of-treatment for ocular edema using an in-eye, bioerodible drug delivery system that includes:
- an immunosuppressive agent
- a bioerodible polymer
- placement in the vitreous of the eye
Claim 1 sets the core scope: treat edema by placing a bioerodible drug delivery system in the vitreous. Dependent claims narrow polymer chemistry and delivery duration.
Stated claims (provided):
- Method for treating edema in an eye by placing a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer in an eye, thereby treating edema, where placement is in the vitreous.
- Method of claim 1, where the polymer comprises a PLGA copolymer.
- Method of claim 1, where the system delivers the immunosuppressive agent for at least about 5 days.
- Method of claim 1, where the system delivers the immunosuppressive agent for at least about 3 weeks.
What is the claim architecture and what limits infringement?
The patent is structured as a single broad method claim with three narrowing dependent features (polymer type, minimum duration of release, minimum time scale). Practically, this creates a two-layer infringement trigger:
-
Independent claim 1 requires three conjunctive elements:
1) treating “edema in an eye”
2) using a bioerodible drug delivery system with immunosuppressive agent + bioerodible polymer
3) placing in the vitreous
-
Dependent claims add hard narrowing conditions:
- Claim 2 narrows the polymer to PLGA copolymer
- Claims 3 and 4 add delivery duration thresholds (>= 5 days and >= 3 weeks, respectively)
Because this is a method claim, infringement hinges on use steps (the treating doctor or treatment system performing placement in the vitreous and achieving treatment), not on possessing the device alone.
Claim-by-Claim Scope and Effective Boundaries
Claim 1: Is “edema” and “immunosuppressive agent” broad or tight?
Claim 1 scope:
- Condition scope: “edema of the eye” is not limited by etiology (for example, diabetic macular edema, postoperative inflammation-related edema, uveitic edema, traction-related edema). The claim language captures any ocular edema treated using the claimed method.
- Mechanism scope: “immunosuppressive agent” is also not limited in your provided text to specific molecules (e.g., corticosteroids are immunosuppressive; calcineurin inhibitors can be; biologics exist but are less likely in bioerodible formats). The term typically expands to a range of immunomodulators, but the actual allowable set depends on the specification. From the claims alone, the set is broad.
- Placement scope: “placing … in the vitreous” is the key anatomic limitation and is likely the strongest boundary against prior art and design-arounds.
Functional delivery scope:
- Claim 1 does not specify release kinetics. It requires a bioerodible drug delivery system but the duration is handled only in dependent claims.
Effective boundary for infringement under claim 1:
- If a product or protocol delivers an immunosuppressive agent using a bioerodible system placed in the vitreous, that use can fall within claim 1 when paired with treatment of ocular edema.
- If placement occurs elsewhere (subretinal, intraretinal, suprachoroidal, anterior chamber) without vitreous placement, claim 1 is not met on the literal placement element.
Claim 2: How narrow is PLGA?
Claim 2 requires the bioerodible polymer comprises a PLGA copolymer.
Practical impact:
- This narrows polymer chemistry to PLGA copolymers. If a competitor uses a different bioerodible polymer (for example, polycaprolactone, polyanhydride, PEG-based biodegradable systems, hyaluronic acid derivatives) the claim 2 path can be avoided.
- Claim 2 does not say “consists of PLGA,” so mixed polymer systems remain potentially arguable if PLGA is a component. Your infringement read-through depends on exact polymer formulation.
Claims 3 and 4: What does delivery duration mean for design-arounds?
Claim 3: system delivers the immunosuppressive agent for at least about 5 days.
Claim 4: system delivers for at least about 3 weeks.
Practical impact:
- These create timed release threshold limitations. For design-around strategy, shorter-release systems can potentially avoid claim 3 and claim 4 while still achieving some edema control through other mechanisms.
- “At least about” introduces tolerance. That typically preserves room for minor measurement differences and release profile variability. Competitors typically target clearly below the threshold rather than marginally below.
Relative positioning:
- Claim 4 is the narrower timing limitation (>=3 weeks). It also implies that a system meeting claim 4 will generally meet claim 3 if release is at least about 3 weeks, unless claim construction interprets them as requiring specific release profiles independent of total duration. In usual reading, claim 4 subsumes claim 3 on duration.
Scope Map: What the claims cover in real treatment practice
Covered use scenarios (most likely capture)
- Vitreous placement of a bioerodible implant, rod, pellet, or similar depot containing an immunosuppressive agent embedded in or associated with a bioerodible polymer, with treatment intent for ocular edema.
- Polymer is PLGA copolymer (for claim 2).
- Release lasts at least 5 days (claim 3) and, for claim 4, lasts at least 3 weeks.
Likely non-covered scenarios (based on claim text)
- Vitreous is not the placement site.
- Non-bioerodible delivery systems (for example, non-degradable reservoirs) unless they still qualify as “bioerodible” on claim construction.
- Systems that do not include an immunosuppressive agent (for claim 1).
Patent Landscape in the United States (U.S. Drug Patent Context)
What can be concluded from the claims alone
Your provided claims imply a technology niche: bioerodible intra-vitreous drug delivery of immunosuppressants for ocular edema, with emphasis on bioerodibility, vitreous placement, and sustained release duration.
However, a complete U.S. landscape requires citation-quality identification of:
- the full patent record for US 8,043,628 (family, assignee, earliest priority, related continuation, specific specification embodiments),
- the operative claims in the issued patent (and whether the provided claims reflect allowed claims verbatim),
- and the nearest prior art patents and relevant Orange Book entries.
Under the constraint that analysis must be complete and accurate, no additional landscape assertions (for example, specific competitor patents, specific expiring dates, or specific overlaps) can be made solely from the claim text you provided.
Still actionable: where the claim is likely to sit in prior art families
Even without naming specific competitor documents, the claim elements identify the likely prior art clusters that would be used by examiners and litigators:
1) Intra-vitreous bioerodible depots
- Prior art likely includes bioerodible polymer depots intended for intravitreal delivery and sustained release.
2) Immunosuppressive drug formulations for ocular inflammation and edema
- Prior art likely includes immunosuppressants formulated for intraocular administration.
3) Anatomic placement limitations
- Prior art may include ocular drug delivery depots in other ocular compartments, and the “vitreous” limitation can be a differentiator.
4) Release duration windows
- Prior art likely includes release profiles for biodegradable systems, where “at least about 5 days” and “at least about 3 weeks” can become differentiating features.
Decision-grade take: strongest claim features
Based strictly on the claim language you provided, the strongest differentiators against many adjacent ocular drug delivery disclosures are:
- “placing … in the vitreous” (anatomic placement is usually difficult to change without altering the drug-delivery platform)
- bioerodible system (not just any intraocular delivery)
- immunosuppressive agent (mechanistic class; broad but still filters out anti-VEGF-only or purely anti-inflammatory non-immunosuppressive agents depending on construction)
- delivery duration thresholds (timing is measurable in release testing)
Freedom-to-Operate (FTO) Implications for U.S. R&D and Investment
How to evaluate infringement risk against US 8,043,628
For any candidate product aimed at ocular edema using sustained immunosuppressive delivery:
Risk rises if all are true:
- intravitreal/vitreous placement is planned
- the depot is bioerodible
- an immunosuppressive agent is included
- the intended release duration matches claim 3 or claim 4 thresholds
Risk drops if at least one is false:
- vitreous placement is avoided (subretinal, suprachoroidal, anterior chamber approaches)
- the delivery system is not bioerodible (or is demonstrably non-bioerodible under claim construction)
- the drug is not an immunosuppressive agent (again dependent on claim construction/specification support)
- release duration is clearly shorter than claim thresholds
Key Takeaways
- US 8,043,628 claim 1 covers a method to treat ocular edema by placing a bioerodible drug delivery system containing an immunosuppressive agent in the vitreous.
- Claim 2 limits the polymer to PLGA copolymer.
- Claims 3 and 4 add minimum release duration thresholds of >= about 5 days and >= about 3 weeks, respectively.
- The landscape implications hinge on three elements that are typically most defensible in litigation: vitreous placement, bioerodibility, and release duration.
FAQs
-
Does US 8,043,628 require a specific immunosuppressive drug?
Not in the claim language you provided; it requires an “immunosuppressive agent,” with specificity dependent on claim construction and specification support.
-
Is vitreous placement required for infringement of claim 1?
Yes. Claim 1 explicitly requires placement “in the vitreous.”
-
What does claim 2 add beyond claim 1?
It restricts the bioerodible polymer to a PLGA copolymer.
-
Can a product avoid claim 4 by shortening release time?
Potentially. Claim 4 requires delivery for at least about 3 weeks; avoiding that threshold is a plausible design-around axis.
-
Is US 8,043,628 a device claim or a method claim?
It is a method for treating edema using a placement step in the vitreous.
References
[1] United States Patent 8,043,628 (claims provided in user prompt).
More… ↓
⤷ Start Trial
|
